Kalvista Pharmaceuticals Inc (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par sold 500,000 shares of the stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $28.75, for a total transaction of $14,375,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

NASDAQ KALV traded down $0.54 during mid-day trading on Wednesday, reaching $27.68. 123,695 shares of the stock were exchanged, compared to its average volume of 104,850. Kalvista Pharmaceuticals Inc has a 1-year low of $7.73 and a 1-year high of $34.92. The firm has a market cap of $486.80 million, a P/E ratio of -18.09 and a beta of 2.45.

Kalvista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.22. Kalvista Pharmaceuticals had a negative net margin of 70.08% and a negative return on equity of 19.12%. The firm had revenue of $3.89 million for the quarter, compared to analyst estimates of $3.97 million. Analysts anticipate that Kalvista Pharmaceuticals Inc will post -1.65 EPS for the current fiscal year.

Several analysts have recently commented on KALV shares. BidaskClub upgraded shares of Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, March 1st. Zacks Investment Research upgraded shares of Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a research report on Wednesday, January 2nd. ValuEngine upgraded shares of Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. Cantor Fitzgerald reiterated a “buy” rating and issued a $32.00 price target on shares of Kalvista Pharmaceuticals in a research report on Friday, December 14th. Finally, Needham & Company LLC started coverage on shares of Kalvista Pharmaceuticals in a research report on Wednesday. They issued a “buy” rating and a $35.00 price target on the stock. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $28.60.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vivo Capital LLC boosted its holdings in shares of Kalvista Pharmaceuticals by 352.6% in the 3rd quarter. Vivo Capital LLC now owns 1,359,149 shares of the specialty pharmaceutical company’s stock valued at $30,051,000 after purchasing an additional 1,058,824 shares during the last quarter. Polar Capital LLP acquired a new position in shares of Kalvista Pharmaceuticals in the 4th quarter valued at $1,558,000. Vanguard Group Inc. boosted its holdings in shares of Kalvista Pharmaceuticals by 152.4% in the 3rd quarter. Vanguard Group Inc. now owns 296,581 shares of the specialty pharmaceutical company’s stock valued at $6,558,000 after purchasing an additional 179,092 shares during the last quarter. Stonepine Capital Management LLC acquired a new position in shares of Kalvista Pharmaceuticals in the 3rd quarter valued at $3,053,000. Finally, Fosun International Ltd acquired a new position in shares of Kalvista Pharmaceuticals in the 4th quarter valued at $2,444,000. Hedge funds and other institutional investors own 77.31% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/insider-selling-kalvista-pharmaceuticals-inc-kalv-major-shareholder-sells-500000-shares-of-stock/2905033.html.

About Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Featured Story: Understanding debt-to-equity ratio in fundamental analysis

Insider Buying and Selling by Quarter for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.